

To improve the lives of patients by creating & developing innovative antibody products



Approved Partnered Products Solid Financial Base

DARZALEX® (daratumumab) / DARZALEX FASPRO™ (daratumumab & hyaluronidase-fihj)¹, Kesimpta® (ofatumumab)², TEPEZZA® (teprotumumab)³ Azerra® (ofatumumab)⁴



Our Own Clinical Pipeline Potential first-in-class / Best-in-class

Tisotumab vedotin⁵, enapotamab vedotin, HexaBody®-DR5/DR5, epcoritamab⁶, DuoBody-PD-L1x4-1BB (GEN1046)⁷, DuoBody-CD40x4-1BB (GEN1042)⁷ DuoHexaBody®-CD37 (GEN309)⁶ & DuoBody®-CD3x5T4 (GEN1044)⁶



Partner-owned Programs in the Clinic Programs Built on Genmab's Innovation

15 in clinical development with partners with royalty streams for Genmab should they come to market. Includes 7 DuoBody products with Janssen



Technologies & Preclinical R&D Engine: Powerhouse of Innovation

DuoBody tech., HexaBody tech., DuoHexaBody tech., HexElect® tech. & Rich preclinical pipeline incl. HexaBody-CD38 (GEN3014)⁸



Our Three-pronged Strategy

- Focus on core competence
- Turn science into medicine
- Build a profitable & successful biotech



Our Vision

By 2025, our own product has transformed cancer treatment and we have a pipeline of knock-your-socks-off antibodies



Proprietary technologies allow us to build a world-class pipeline

Match in-house expertise with strategic partnerships



Deep insight into antibody biology & disease targets

Strong pipeline of first-in-class / best-in-class products

2020 Guidance

Income Statement	DKKM	USDM ⁹
Revenue	9,250 – 9,850	1,423 – 1,515
Operating expenses	(3,850) – (3,950)	(592) – (608)
Operating income	5,350 – 5,950	823 - 915

⁹USD 1.00 = DKK 6.50

DKK
96B
~USD 14B¹⁰
2019 year-end market cap


¹⁰USD 1.00 = DKK 6.6759

DKK
2,728M
~USD 408M¹⁰
2019 operating expenses
87% invested in R&D

DKK
5,366M
~USD 803M¹⁰
2019 revenue
77% increase vs 2018

DKK
10,971M
~USD 1,643M¹⁰
2019 year end cash position

Revenue MDDK (~MUSD¹⁰)



Innovation Powerhouse

Genmab Proprietary¹¹ Products

Product	Target	Rights	Indications	Most Advanced Dev. Phase					
				Pre-clin.	I	I/II	II	III	Apr.
Tisotumab vedotin	TF	50:50 Genmab Seagen	Cervical cancer Ovarian cancer Solid tumors						
Enapotamab vedotin	AXL	Genmab	Solid tumors						
Epcoritamab	CD3, CD20	50:50 Genmab AbbVie	Hem. malign.						
DuoBody-PD-L1x4-1BB	PD-L1, 4-1BB	50:50 Genmab BioNTech	Solid tumors						
DuoBody-CD40x4-1BB	CD40, 4-1BB	50:50 Genmab BioNTech	Solid tumors						
HexaBody-DR5/DR5	DR5	Genmab	Solid tumors						
DuoHexaBody-CD37	CD37	50:50 Genmab AbbVie	Hem. malign.						
DuoBody-CD3x5T4	5T4	50:50 Genmab AbbVie	Solid tumors						

IND/CTAs in 2020: HexaBody-CD38¹²

Products Created by Genmab¹³

Daratumumab	CD38	Janssen ¹⁴	MM AL Amyloidosis Non-MM blood cancers						
Ofatumumab	CD20	Novartis ^{14,15}	RMS						
Teprotumumab	IGF-1R	Horizon ¹⁴	TED dcSSc						

Partner-owned products incorporating Genmab's Innovation¹⁶

Amivantamab	EGFR, cMet	Janssen	NSCLC						
Teclistamab	BCMA, CD3	Janssen	R/R MM						
Camidanlumab tesirine	CD25	ADC Therapeutics	R/R Hodgkin lymphoma Solid tumors						
PRV-015 (AMG 714)	IL-15	Provention Bio	Celiac disease						
Mim8	FIX(a), FX	Novo Nordisk	Hemophilia A						
Talquetamab	GPRC5D, CD3	Janssen	R/R MM						
JNJ-63709178	CD123, CD3	Janssen	AML						
JNJ-63898081	PSMA, CD3	Janssen	Solid tumors						
JNJ-67571244	CD33, CD3	Janssen	R/R AML; MDS						
JNJ-70218902	Undisclosed	Janssen	Solid tumors						
HuMax-IL8	IL8	BMS	Adv. cancers						
Lu AF82422	alpha-synuclein	Lundbeck	Parkinson's						

~20 active pre-clinical programs Partnered & proprietary programs: HuMab, Duo-Body, DuoHexaBody and HexaBody

Products & Technologies

Tisotumab vedotin

- ADC in development to treat solid tumors
- Very favorable data, Ph 2 cervical cancer
- Ph 2 studies in ovarian & other solid tumors
- 50:50 agreement w/ Seagen

Enapotamab vedotin

- ADC in development to treat solid tumors
- Ph 1/2 trial for multiple solid tumors

HexaBody-DR5/DR5 (GEN1029)

- Proprietary antibody therapeutic
- Phase 1/2 trial in solid tumors

Epcoritamab (DuoBody-CD3xCD20)

- Bispecific antibody created w/ DuoBody tech
- Phase 1/2 trial in B-cell malignancies
- 50:50 collaboration w/ AbbVie

DuoBody-PD-L1x4-1BB (GEN1046)

- Bispecific antibody created w/ DuoBody tech
- Phase 1/2 trial in solid tumors
- 50:50 agreement w/ BioNTech

DuoBody-CD40x4-1BB (GEN1042)

- Bispecific antibody created w/ DuoBody tech
- Phase 1/2 trial in solid tumors
- 50:50 agreement w/ BioNTech

DuoHexaBody-CD37 (GEN3009)

- Based on combo DuoBody & HexaBody
- FiH trial commenced
- 50:50 collaboration w/ AbbVie

DuoBody-CD3x5T4 (GEN1044)

- Bispecific antibody created w/ DuoBody tech
- FiH trial commenced
- 50:50 collaboration w/ AbbVie

Kesimpta (ofatumumab)

- SubQ formulation approved in US for RMS¹⁴
- In development by Novartis

Founded: 1999

Exchanges: CSE / Nasdaq

Symbol: GMAB

Shares outstanding: 65,498,346

Market Cap as of Nov. 4, 2020:

DKK 154B (~USD 24,064M)

DARZALEX (daratumumab) / DARZALEX FASPRO (daratumumab & hyaluronidase-fihj)

- First-in-class CD38 antibody
- Approved in certain territories for various multiple myeloma (MM) indications¹⁴
- First & only SC CD38 antibody approved
- In development by Janssen
- 2019 net sales by Janssen: \$2,998M, DKK 3,132M royalties to Genmab

TEPEZZA (teprotumumab)

- Dev. & manufactured by Horizon Therapeutics
- Approved in US for thyroid eye disease¹⁴
- Created under collaboration with Roche
- Under terms of agreement with Roche, Genmab to receive mid-single digit royalties on sales

DuoBody Platform

- Bispecific antibody technology platform
- Potential in cancer, autoimmune, infectious, cardiovascular, central nervous system diseases & hemophilia
- Multiple commercial & research collaborations

HexaBody Platform

- Enhanced potency antibody technology platform
- Broadly applicable technology that builds on natural antibody biology

DuoHexaBody Platform

- Antibody technology that combines DuoBody & HexaBody platforms
- Creates bispecific antibodies with target-mediated enhanced potency

HexElect Platform

- Antibody technology platform inspired by HexaBody platform
- Combines dual targeting with enhanced selectivity & potency

Executive Management:

Jan G. J. van de Winkel, Ph.D. President & CEO

Anthony Pagano, EVP & CFO

Judith Klimovsky M.D., EVP & CDO

Anthony Mancini, EVP & COO

¹¹Certain product candidates in development with partners, as noted

¹²Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen Biotech, Inc.

¹³Out-licensed products marketed by partner

¹⁴See local country prescribing information for precise indications

¹⁵Also approved as Arzerra for certain CLL indications, not in active clinical development

¹⁶Products under development by a third-party incorporating Genmab's technology and innovation.